Quarterly Activities Update: Encouraging Growth for geneType Commercial Test Volume
July 28, 2023 08:00 ET
|
Genetic Technologies Ltd
MELBOURNE, Australia, July 28, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE, “Company”, “GTG”), a global leader in guideline-driven genomics-based testing in health, wellness...
Genetic Technologies Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
July 21, 2023 08:00 ET
|
Genetic Technologies Ltd
MELBOURNE, Australia, July 21, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, “Company”) a global leader in genomics-based tests in health, wellness and serious disease,...
GeneType featured on U.S. National TV to raise Breast Cancer Awareness
May 23, 2023 08:00 ET
|
Genetic Technologies Ltd
MELBOURNE, Australia, May 23, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) a global leader in genomics-based tests in health, wellness and serious...
New Publication Validates geneType for Melanoma Risk Assessment
April 28, 2023 08:00 ET
|
Genetic Technologies Ltd
MELBOURNE, Australia, April 28, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) a global leader in genomics-based tests in health, wellness and...
Quarterly Business Update – March 2023
April 27, 2023 08:00 ET
|
Genetic Technologies Ltd
MELBOURNE, Australia, April 27, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, ”Company”, “GTG”), a global leader in guideline-driven genomics-based testing in health,...
Publication Validates geneType Prostate Cancer Risk Test
April 19, 2023 08:00 ET
|
Genetic Technologies Ltd
MELBOURNE, Australia, April 19, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) a global leader in genomics-based tests in health, wellness and...
GeneType Multi-Risk Test now includes Melanoma, Pancreatic Cancer & Atrial Fibrillation
March 27, 2023 08:00 ET
|
Genetic Technologies Ltd
MELBOURNE, Australia, March 27, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and...
Back-to-back Studies Validate geneType Breast Cancer Risk Test
March 13, 2023 08:00 ET
|
Genetic Technologies Ltd
MELBOURNE, Australia, March 13, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and...
New Publication Highlights geneType’s Ability to Detect Breast Cancer Earlier and Provide Data for Risk Stratification
February 09, 2023 08:00 ET
|
Genetic Technologies Ltd
MELBOURNE, Australia, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and...
Genetic Technologies Announces Closing of $5 Million Registered Direct Offering
February 07, 2023 10:00 ET
|
Genetic Technologies Ltd
MELBOURNE, Australia, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven...